Denali Advisors LLC Has $7.59 Million Position in Amphastar Pharmaceuticals, Inc. $AMPH
Denali Advisors LLC significantly increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 41.1% in Q2, bringing its total holdings to 375,965 shares valued at $7.59 million. Despite Amphastar exceeding Q2 earnings expectations with $0.91 EPS against a $0.62 consensus, analyst sentiment remains cautious, with a "Reduce" rating and a $22.50 price target. This comes amidst insider share sales and institutional investors collectively owning a majority of the company's stock.
Barclays Issues Positive Forecast for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price
Barclays has increased its price target for Amphastar Pharmaceuticals (NASDAQ:AMPH) from $20 to $23, maintaining an "equal weight" rating and suggesting a 7.1% upside. Despite this, analyst sentiment remains cautious with a MarketBeat consensus rating of "Reduce" and an average target of $22.50. The company recently surpassed quarterly expectations, reporting $0.91 EPS against a $0.62 estimate and revenue of $183.9 million, exceeding the $179.9 million forecast.
Amphastar (NASDAQ: AMPH) insider lines up stock sale after option exercise
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) insider Floyd Petersen plans to sell 47,101 shares of common stock, valued at $989,121, through UBS Financial Services Inc. This sale is being executed under Rule 144, following an option exercise for cash on August 18, 2026, which is also the proposed sale date. The transaction represents a small fraction of the 44,092,000 shares outstanding.
Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating
Barclays has increased its price target for Amphastar Pharmaceuticals (AMPH) to $23 from $20, while maintaining an Equalweight rating on the stock. This adjustment comes after the company recently reported its Q2 2026 earnings, posting an adjusted EPS of $0.91, significantly exceeding the FactSet estimate of $0.62. Amphastar also reported Q2 revenue of $183.9M, surpassing the FactSet estimate of $179.9M.
Lead Independent Director Richard Prins Sold A Bunch Of Shares In Amphastar Pharmaceuticals
Amphastar Pharmaceuticals' Lead Independent Director, Richard Prins, recently sold US$162k worth of shares at an average price of US$20.30, reducing his holding by 27%. This was the largest insider sale in the past year for the company. While the sale occurred near the current stock price, which is not ideal, insiders still own 10% of Amphastar Pharmaceuticals, valued at about US$88 million.
Amphastar Pharmaceuticals (AMPH) Director Richard Prins Sells 7,973 Shares
Richard Prins, a director at Amphastar Pharmaceuticals (AMPH), sold 7,973 shares of the company for approximately $161,852 on August 11, 2026. This sale contributes to a trend of insider selling at AMPH over the past year, with no insider buys recorded. Despite the insider selling, GuruFocus pegs the stock as "Significantly Undervalued" with a price-to-GF-Value ratio of 0.57.
Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. – MUN:29A
This article focuses on the enterprise value to EBITDA forward for Amphastar Pharmaceuticals, Inc. (MUN:29A) as listed on the Munich Stock Exchange. It indicates that the market is currently closed with no trades. The information is presented within the financial section of a trading platform.
Amphastar director Richard Prins disposes of shares valued at $161,851
Amphastar Pharmaceuticals director Richard K. Prins sold 7,973 shares of the company's common stock for $161,851. This transaction occurred on August 11, 2026, with shares priced at $20.3 each, leaving him with 29,625 shares. The sale follows the company's strong Q2 2026 revenue of $183.9 million, surpassing analyst estimates, driven by new product success despite a 25% year-to-date stock decline.
Richard Prins Sells 7,973 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock
Richard Prins, a director at Amphastar Pharmaceuticals (NASDAQ:AMPH), sold 7,973 shares of the company's stock for over $161,000, reducing his direct holdings by more than 21%. Despite the sale and a "Reduce" consensus rating from analysts, the company recently reported strong quarterly earnings, beating revenue and EPS estimates. Institutional investors hold a significant stake of 65.09% in Amphastar Pharmaceuticals.
Director Richard Prins sells 7,973 Amphastar (AMPH) shares at $20.30
Richard K. Prins, a director at Amphastar Pharmaceuticals, Inc. (AMPH), sold 7,973 shares of the company's common stock at a price of $20.30 per share on August 11, 2026. This transaction, reported as an open market or private sale, leaves Prins with 29,625 shares of Amphastar common stock directly held. The Form 4 filing details this insider trading activity.
Amphastar CFO William Peters sells $183,886 in company stock
Amphastar Pharmaceuticals CFO William J. Peters sold 8,180 shares of company stock for $183,886 on August 7, 2026, as part of a Rule 10b5-1 trading plan. Concurrently, he acquired 5,053 shares through employee stock option exercises for $99,998. Following these transactions, Peters beneficially owns 172,846 shares of Amphastar common stock.
Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters Sells 8,180 Shares
Amphastar Pharmaceuticals' CFO, William Peters, sold 8,180 shares of the company's stock for a total of $183,886.40, reducing his holdings by 4.52%. This transaction occurred under a pre-arranged Rule 10b5-1 trading plan. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, though analyst sentiment for the stock remains cautious with a consensus "Reduce" rating.
Amphastar (AMPH) CFO exercises options and sells 8,180 shares in 10b5-1 trade
Amphastar Pharmaceuticals' CFO, William J. Peters, exercised 5,053 employee stock options at $19.79 per share and subsequently sold 8,180 shares of common stock at $22.48 per share on August 7, 2026. This sale was conducted under a Rule 10b5-1 trading plan adopted on March 10, 2026. Following these transactions, Peters holds 172,846 shares of common stock and zero employee stock options from that grant.
AMPH (AMPH) schedules Rule 144 stock sale tied to RSU vesting
Amphastar Pharmaceuticals (AMPH) has filed a Rule 144 notice for the proposed sale of 7,973 shares of common stock, valued at $161,931.63, through UBS Financial Services Inc. The sale is scheduled for August 11, 2026, and is linked to multiple Restricted Stock Unit (RSU) vesting events that occurred between 2017 and 2025. The filing indicates 44,009,000 shares are outstanding.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Reduce" from Analysts
Amphastar Pharmaceuticals (NASDAQ:AMPH) has received an average "Reduce" recommendation from eight brokerages, with two analysts rating it a "sell" and six a "hold." Despite this cautious sentiment and an average 12-month price target of $22.00, the company recently surpassed earnings expectations, reporting $0.91 EPS against a $0.62 consensus and $183.9 million in revenue. Institutional investors hold 65.09% of the company, whose shares opened at $20.31, falling within its 52-week range of $16.65 to $31.26.
Weekly Recap: Amphastar Q2 growth, $100M BAQSIMI and IMS FDA warning
Amphastar Pharmaceuticals (AMPH) reported strong Q2 2026 revenue of $183.9M, a 5% year-over-year increase, significantly boosted by a $100M payment from a $175M BAQSIMI milestone. However, the company faces potential increased remediation costs and slowed batch releases due to an FDA warning letter issued to IMS.
Results: Amphastar Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
This article provides an analysis of Amphastar Pharmaceuticals, Inc.'s recent financial performance, highlighting that the company exceeded consensus expectations. It is anticipated that analysts will update their estimates based on these strong results. The piece will likely delve into the specific financial metrics that contributed to the outperformance and discuss the potential implications for the company's future outlook and stock valuation.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $20.00 by Analysts at Piper Sandler
Piper Sandler has reduced its price target for Amphastar Pharmaceuticals (AMPH) to $20.00 from $21.00, maintaining a "neutral" rating despite the company's recent earnings beat. While Amphastar exceeded analyst expectations with adjusted EPS of $0.91 and revenue of $183.9 million, overall analyst sentiment remains cautious, with a consensus "Reduce" rating and an average target price of $22.00. Other firms like Wells Fargo and Barclays also set their price targets at $20.00, indicating a conservative outlook on the stock's future performance.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded by Wall Street Zen to "Strong-Buy" Rating
Amphastar Pharmaceuticals (NASDAQ:AMPH) received an upgrade from Wall Street Zen to a "strong-buy" rating, despite a more cautious "reduce" consensus rating from other analysts. The company's recent quarterly results surpassed expectations with revenues of $183.9 million and adjusted EPS of $0.91, outperforming estimates. Institutional investors hold a significant portion of Amphastar's outstanding shares, while the stock currently trades below its 200-day moving average.
Amphastar Pharmaceuticals, Inc. SEC Filing (Aug 7, 2026)
This article reports on Amphastar Pharmaceuticals, Inc.'s SEC Form 144 filing from August 7, 2026. The filing indicates a proposed sale of securities, detailing the class of securities, the broker involved (UBS Financial Services, Inc.), the number of shares, aggregate market value, and the date of sale. It also specifies that the securities were acquired through RSU Vesting in March 2024.
Amphastar Pharmaceuticals, Inc. (AMPH) stock price, news, quote and history
This article provides a comprehensive overview of Amphastar Pharmaceuticals, Inc. (AMPH) stock, including its current price, historical data, financial performance, and analyst ratings. It details the company's product portfolio, which includes various injectable, inhalation, and intranasal products, and lists key financial metrics and comparisons with similar companies.
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
Amphastar Pharmaceuticals reported a 5% year-over-year revenue increase in Q2 2026, reaching $183.9 million, driven by new product launches like ipratropium bromide inhalation. Despite a slight dip in net income, diluted EPS rose, and the company is addressing an FDA warning letter at its IMS subsidiary while continuing pipeline investments. Management maintains its corporate sales growth outlook for 2026, with an insulin biosimilar on track for 2027 commercialization.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Amphastar Pharmaceuticals reported net revenues of $183.9 million for the second quarter of 2026, marking a 5% increase year-over-year. GAAP net income was $30.3 million ($0.67 per share), and adjusted non-GAAP net income was $40.8 million ($0.91 per share). The company highlighted overall revenue growth, expanded gross margins, successful new product launches like ipratropium bromide, and continued advancement in its generic and proprietary development pipelines, despite navigating pricing and competitive dynamics.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported better-than-expected Q2 CY2026 results, with revenue of $183.9 million exceeding analyst estimates by 2% and non-GAAP profit of $0.91 per share significantly beating consensus estimates. The company achieved 5.4% year-on-year revenue growth and highlighted successful key goals including overall revenue growth, expansion of gross margins, new product launches, and advancement in its development pipelines. Despite a decrease in operating margin this quarter, the company's long-term performance shows solid compounded annual growth rates for sales and EPS.
Amphastar Pharmaceuticals (NASDAQ: AMPH) Q2 revenue rises 5% with margin gains
Amphastar Pharmaceuticals reported a 5% increase in Q2 2026 net revenues to $183.9 million, driven by growth in new products like Ipratropium bromide, despite declines in others such as BAQSIMI and Glucagon. The company achieved a gross margin expansion to 50.8%, although GAAP net income slightly decreased compared to the prior year. Amphastar also highlighted its robust pipeline, including several ANDA and biosimilar insulin candidates targeting markets exceeding $6.3 billion.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Amphastar Pharmaceuticals, Inc. reported net revenues of $183.9 million for the second quarter of 2026, marking a 5% increase year-over-year. GAAP net income was $30.3 million ($0.67 per share), while adjusted non-GAAP net income reached $40.8 million ($0.91 per share). The company highlighted continued execution of its diversification strategy, including new product launches and advancement of its generic and proprietary pipelines.
Pacer Advisors Inc. Buys 83,739 Shares of Amphastar Pharmaceuticals, Inc. $AMPH
Pacer Advisors Inc. increased its stake in Amphastar Pharmaceuticals by 47.1% in the first quarter, purchasing 83,739 additional shares, bringing its total holdings to 261,483 shares valued at approximately $5.1 million. Despite this institutional interest, analyst sentiment remains cautious with a "Reduce" consensus rating and an average price target of $22, following Amphastar's recent quarterly earnings miss. The company's stock is trading near its 52-week low amidst these financial and analyst concerns.
Amphastar Pharmaceuticals, Inc. (AMPH): Investor Outlook Reveals 8.80% Upside Potential
Amphastar Pharmaceuticals (NASDAQ: AMPH) is a biopharmaceutical company with a diverse product portfolio showing an 8.80% upside potential from its current stock price of $20.22, with an average target price of $22.00. Despite its strong free cash flow and return on equity, caution is advised due to an overbought RSI and cautious analyst sentiment with no buy ratings. The company's innovative product lineup and international expansion are key strengths for future growth.
Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP significantly increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 12.7% in the first quarter, now owning over 2 million shares. Despite this institutional interest, Amphastar's recent quarterly earnings missed analyst expectations for both EPS and revenue, contributing to a "Reduce" consensus rating from analysts with an average price target of $22. The stock recently opened at $20.22, with 65.09% of its shares held by institutional investors and hedge funds.
Arrowstreet Capital Limited Partnership Has $6.37 Million Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH
Arrowstreet Capital Limited Partnership reduced its stake in Amphastar Pharmaceuticals by 41.9% in Q1 2026, holding 325,291 shares valued at $6.37 million. Despite this, institutional ownership remains high at 65.09%, with other firms like Dimensional Fund Advisors and State Street increasing their positions. The stock currently has a "Reduce" consensus rating from analysts, with an average price target of $22, following recent quarterly earnings that missed estimates.
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Analysts expect Amphastar Pharmaceuticals (AMPH) to report a year-over-year decline in earnings for Q2 2026, despite a projected increase in revenues. The Zacks Earnings ESP indicates a potential negative surprise for AMPH, compounded by a Zacks Rank of #5 (Strong Sell). In contrast, Supernus Pharmaceuticals (SUPN), a peer in the same industry, shows a strong potential for beating analyst EPS estimates due to a positive Earnings ESP and a Zacks Rank of #
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced it will release its second-quarter 2026 financial results after market close on Thursday, August 6, 2026. The company will also host a conference call at 2:00 p.m. Pacific Time on the same day to discuss these results. Investors can access the call via phone or through the company's website.
Amphastar Pharmaceuticals Inc (AMPH) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of Amphastar Pharmaceuticals Inc (AMPH)'s financial health, indicating a stable financial status and high operating efficiency with a current score of 8.70. The company reported a significant year-over-year increase in net profit by 74.61%, despite a modest revenue increase of 0.38%. The report details scores for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns, though much of the specific financial data is noted as not yet disclosed.
Amphastar Pharmaceuticals (AMPH) Projected to Release Quarterly Earnings on Thursday
Amphastar Pharmaceuticals (AMPH) is expected to release its Q2 2026 earnings after market close on Thursday, August 6th, with analysts projecting $0.66 EPS and $179.9210 million in revenue. The company previously missed Q1 2026 consensus estimates, reporting $0.42 EPS against an anticipated $0.70. Institutional investors have recently adjusted holdings, and analysts have issued updated price targets and ratings, with a consensus "Reduce" rating and a $22.00 target price.
Amphastar Sets Aug. 6 Webcast for Second-Quarter Results
Amphastar Pharmaceuticals (NASDAQ: AMPH) announced it will release its second-quarter 2026 financial results on Thursday, August 6, 2026, after the market closes. The company will also host a conference call at 2:00 p.m. Pacific Time to discuss the results, with access available via dial-in numbers and a webcast on its investor website. A replay of the webcast will be available within 24 hours of the live call.
3 Reasons AMPH is Risky and 1 Stock to Buy Instead
Amphastar Pharmaceuticals (AMPH) has seen its stock price drop significantly, leading to questions about its investment potential. The article highlights three reasons for caution: lackluster revenue growth, limited distribution channels due to its small size in a scale-driven industry, and a shrinking adjusted operating margin. Given these shaky fundamentals, the author suggests that despite an optically cheap valuation, there are more exciting and higher-quality stocks available.
Amphastar Pharmaceuticals Inc (AMPH) Cash Flow
This article provides a detailed cash flow statement for Amphastar Pharmaceuticals Inc (AMPH), covering annual and quarterly data across operating, investing, and financing activities. It presents financial figures for various cash flow components from FY2012Q4 to FY2026Q1, including net income, capital expenditures, and changes in working capital. The article also includes a FAQ section defining different types of cash flow and specific figures for AMPH.
Amphastar Pharmaceuticals Inc (AMPH) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Amphastar Pharmaceuticals Inc (AMPH), listing major shareholders such as Applied Physics & Chemistry Laboratories, Inc., BlackRock Institutional Trust Company, N.A., and key individual investors. It also provides a breakdown of shareholder types, institutional holdings over several quarters, and shareholder activity including changes in holdings. Additionally, the report identifies related ETFs that hold AMPH shares.
Rice Hall James & Associates LLC Increases Position in Amphastar Pharmaceuticals, Inc. $AMPH
Rice Hall James & Associates LLC increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 54.6% in the first quarter, now holding 187,348 shares valued at $3.67 million. Despite institutional ownership accounting for 65.09% of the company, Amphastar Pharmaceuticals missed first-quarter earnings and revenue estimates and faces a consensus "Reduce" rating from analysts with an average price target of $22.00. The stock has experienced a significant decline from its 52-week high, opening at $18.72 on Monday near its 52-week low.
Amphastar Pharmaceuticals Inc (AMPH) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Amphastar Pharmaceuticals Inc (AMPH) focusing on its dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years, indicating no recent payouts. The page also displays current stock price information, market cap, and P/E ratio for AMPH.
AMPH|Amphastar Pharmaceuticals Inc|Price:19.180|Chg%:+0.460
This article provides a comprehensive stock analysis of Amphastar Pharmaceuticals Inc (AMPH) by TradingKey. It highlights the company's relatively healthy fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. While institutional ownership is very high and analysts generally rate it as a 'Hold' with a target price of $22.00, the stock has recently traded sideways, suggesting suitability for range-bound swing trading despite a weak market performance.
Amphastar Pharmaceuticals Inc (AMPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Amphastar Pharmaceuticals Inc (AMPH), categorizing it by business segments and regional contributions. Key product revenues are highlighted, such as Other products, BAQSIMI, Primatene Mist, Epinephrine, and Glucagon. The dominant source of regional revenue for AMPH is the United States, followed by France and China.
AMPH5896384 Bond Profile — Key Metrics
This article provides key financial metrics for the AMPH5896384 bond issued by Amphastar Pharmaceuticals, Inc. It details the bond's coupon rate, issue and maturity dates, outstanding amount, face value, and minimum denomination. The company profile highlights its focus on developing and manufacturing generic and proprietary injectable, inhalation, and intranasal products.
AMPH5896384 Bond Coupon Profile — Rate & Payments
This article provides the coupon profile for the Amphastar Pharmaceuticals, Inc. bond, identified as AMPH5896384. It details that the bond has a current coupon rate of 2.00% and the next interest payment is scheduled for September 15, 2026. The information covers the bond's nominal yield and upcoming payment schedule.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded by Zacks Research to "Hold" Rating
Zacks Research upgraded Amphastar Pharmaceuticals
Quantedge Capital Pte Ltd Sells 78,200 Shares of Amphastar Pharmaceuticals, Inc. $AMPH
Quantedge Capital Pte Ltd significantly reduced its stake in Amphastar Pharmaceuticals, Inc. by 85.3% in the first quarter, selling 78,200 shares. This move leaves the firm with 13,500 shares valued at $264,000, following Amphastar's Q1 earnings miss and Wall Street's cautious "Reduce" rating with a $22 consensus price target. Despite this, other institutional investors have increased their holdings, and the stock currently has a market cap of $863.72 million.
US3209RAB9 Bond Coupon Profile — Rate & Payments
This article provides a coupon profile for the Amphastar Pharmaceuticals, Inc. bond with CUSIP US3209RAB9, maturing on March 15, 2029. It details the current coupon rate of 2.00% and states that the next payment is scheduled for September 15, 2026. The page offers an overview of interest payments and mentions the availability of more in-depth coupon data for users.
US3209RAB9 Bond Profile — Key Metrics
This article provides key metrics for the US3209RAB9 bond issued by Amphastar Pharmaceuticals, Inc. It details the bond's coupon rate, issue and maturity dates, outstanding amount, and face value. The profile also includes a brief description of Amphastar Pharmaceuticals, Inc. and its business operations.
Dimensional Fund Advisors stake in Amphastar Pharmaceuticals (AMPH) hits 5.2%
Dimensional Fund Advisors LP has reported a beneficial ownership of 2,305,107 shares of Amphastar Pharmaceuticals (AMPH) common stock, which represents 5.2% of the class as of June 30, 2026. The firm exercises sole voting power over 2,251,660 shares and sole dispositive power over all 2,305,107 shares, held on behalf of client funds for which it provides advisory services. Dimensional disclaims beneficial ownership beyond Section 13(d) reporting, and no individual client fund holds more than 5% of Amphastar's stock.
Form 4 Amphastar P For: 13 July By Investing.com
The article is a brief financial post from Investing.com, likely announcing a Form 4 filing for Amphastar Pharmaceuticals on July 13th. The content primarily consists of navigation links, advertisements, and market data, with very little substantive information about the Form 4 itself. It seems to function more as a placeholder for a news item that would typically contain details of insider transactions.
